FrederickRUelandMD

Obstetrics & Gynecology • Lexington, KY

General Obstetrics, Gynecologic Oncology

Professor

Join to view full profile

Dr. Ueland is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ueland's full profile

Already have an account?

Office
800 Rose Street
Lexington, KY 40536
Phone+1 859-257-1613

Summary

Dr. Frederick Ueland is Professor and Director of Gynecologic Oncology at the University of Kentucky Albert B. Chandler Hospital in Lexington, KY. He is also the Chief Medical Officer and Director of Clinical Operations for the Markey Cancer Center. He received his medical degree from Wake Forest School of Medicine and did a General Surgery Internship, Residency in Obstetrics and Gynecology, and Fellowship in Gynecologic Oncology at the University of Kentucky. He has been in practice 27 years. He specializes in gynecologic oncology with a specialty interest in ovarian cancer and comprehensive gynecologic surgery.

Education & Training

University of Kentucky College of MedicineResidency, Obstetrics and Gynecology, 1991 - 1995
University of Kentucky College of MedicineInternship, Surgery, 1990 - 1991
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 1990
Stanford UniversityBS, Biology, honors degree, 1981 - 1985
University of Kentucky College of MedicineFellowship, Gynecologic Oncology

Certifications & Licensure

KY State Medical License 1991 - 2025
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly
Best Doctors in America Teladoc Health
Top Doctors in America Castle Connolly
Vitals Patients Choice Award American Registry
Join now to see all

Clinical Trials

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
Active, not recruiting
Phase 2
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 13
Completed
Phase 2
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Start of enrollment: 2010 Feb 08
Active, not recruiting
Phase 2
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
Intraoperative Pathological Evaluation for Surgical Treatment & Staging for Endometrial Cancer Start of enrollment: 2012 Jan 01
Completed
Phase 2
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
Active, not recruiting
Phase 2, Phase 3
Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors Start of enrollment: 2016 Sep 12
Completed
Not Applicable
Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation Start of enrollment: 2016 Jan 29
Active, not recruiting
Not Applicable
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer Start of enrollment: 2021 Mar 17
Active, not recruiting
Phase 1
Comparison of Nodal Staging in Endometrial Cancer Start of enrollment: 2021 Nov 05
Terminated
Phase 3
Roles: Sponsor-Investigator, Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

52 citations
Predicting risk of malignancy in adnexal masses.
John M. McDonald, Stacey Doran, Christopher P. DeSimone, Frederick R. Ueland, Paul D. DePriest
Obstetrics and Gynecology. 2010-04-01
323 citations
Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type
Leora Witkowski, Jian Carrot-Zhang, Steffen Albrecht, Somayyeh Fahiminiya, Nancy Hamel
Nature Genetics. 2014-05-01
52 citations
Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay.
Rachel W. Miller, Alan Smith, Christopher P. DeSimone, Leigh G. Seamon, S. Goodrich
Obstetrics and Gynecology. 2011-06-01

Journal Articles

Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma
Frederick R Ueland, Esther Elishaev, Tanja Pejovic, Todd B Sheridan, Terry Morgan, Joseph L Kelley, Malcolm S Ross, Stephen H Bush, Ardeshir Hakam, Lynda D Roman, Meri..., Annals of Surgical Oncology
Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma
Lynda D Roman, Terry Morgan, Joseph L Kelley, Todd B Sheridan, Stephen H Bush, Merieme M Klobocista, Miriam D Post, Malcolm S Ross, Frederick R Ueland, Ardeshir Hakam,..., Annals of Surgical Oncology

Other

Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum
Ueland FR, Li AJ
http://www.uptodate.com/contents/serum-biomarkers-for-evaluation-of-an-adnexal-mass-for-epithelial-c
UpToDate, Wolters Kluwer Health - 2013-04-17

Press Mentions

UK Study Shows Combination Therapy May Potentially Improve Ovarian Cancer Patient OutcomesSeptember 28th, 2021
Preventing Cancer Recurrence with Coffee? Markey Launches Unique Clinical TrialApril 26th, 2021
Cancer Centers Cope with COVID-19 SurgeNovember 30th, 2020